Browse articles from EyeWorld.org related to AMD. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ FDA approves suprachoroidal injection for macular edema associated with uveitis ➤ FDA approves first-of-its-kind approach to treat wet AMD ➤ Digital therapeutic for pediatric amblyopia receives FDA premarket approval ➤ Ocular insert for dry eye does not meet Phase 2 primary endpoint ➤ Study: Prozac as a possible treatment for AMD ➤ ASCRS news and events
➤ Positive topline results from Phase 3 trial for first-in-class dry eye drop ➤ Study: Long-term efficacy of neuromyelitis optica spectrum disorder treatment ➤ Long-term data from gene therapy injection for wet AMD ➤ Positive data from Phase 1/2 trial of gene therapy for geographic atrophy ➤ Ophthalmic device company partners with augmented reality tech company
➤ Patient enrollment complete for Phase 2 trial of DED drug candidate ➤ New investigational drug candidates for cornea, glaucoma, and wet AMD ➤ IND filed for glaucoma drug candidate ➤ Collaboration for one-time treatment of several retinal conditions ➤ ASCRS news and events
➤ Study: Standalone trabeculotomy/viscodilation 24-month outcomes ➤ Proof of concept for dropless immunosuppression after PK ➤ Topline Phase 2 data for high-dose aflibercept in wet AMD ➤ Companies enter licensing agreement for investigational ophthalmic therapies ➤ ASCRS news and events
➤ Study: Music reduces anxiety, hypertensive events in cataract surgery ➤ Phase 2 study results for investigational dry AMD treatment ➤ Phase 3 topline results for wet AMD therapeutic ➤ FDA accepts BLA for faricimab ➤ ASCRS news and events
➤ New visual prosthesis heads to clinical trial ➤ FDA grants Fast Track designation to investigational wet AMD therapy ➤ Patient enrollment complete in Phase 3 trial for investigational, first-in-class eye drop for DED ➤ FDA agrees to pivotal trial design for investigational treatment of geographic atrophy secondary to AMD ➤ ASCRS news and events
➤ Survey: 96% of ophthalmologists vaccinated against COVID-19 ➤ Phase 2b/3 results from trial for Demodex blepharitis ➤ Data from ongoing Phase 2a study of therapy for geographic atrophy ➤ First patient enrolled in Phase 2 study of nasal spray for neurotrophic keratopathy ➤ Next ASCRS Journal Club on July 8
➤ Early termination of study evaluating Beovu ➤ NDA resubmitted to FDA for investigational macular edema treatment ➤ First peer-reviewed paper on visual recovery in a blind patient treated with optogenetic therapy ➤ Study: New riboflavin formulation enhances transepithelial crosslinking ➤ Enrollment complete for blepharitis trial ➤ Companies partner to develop human-induced pluripotent stem cell-derived therapies for ocular diseases ➤ ASCRS events
When performing cataract surgery, it’s important to be aware of other conditions and comorbidities, including issues with the retina. Several physicians discussed how to handle patients with retina abnormalities prior to cataract surgery.
➤ Investigating adjuvant therapy to DSO for Fuchs ➤ FDA approves loteprednol etabonate ophthalmic gel ➤ Pilot study: Photobiomodulation improves BCVA in patients with dry AMD ➤ Positive interim data in trial for gene therapy for GA ➤ Four Phase 3 studies of faricimab show up to 4-month treatment intervals for DME and wet AMD